Gennex Laboratories Ltd
Ticker: GENNEX
Risky
48/100
☆ Add to Watchlist
Investing Reference
Price
16.43
Market Cap
399.16
Debt/Equity
0.0525
ROE %
9.767
PB
2.0514
Promoter %
23.621
Pledge %
4.116
1Y Rev Growth %
61.897
5Y Rev Growth %
21.216
NP Margin %
12.216
NP Margin 5Y Avg %
9.331
Trading Reference
1M Return %
44.288
6M Return %
25.997
1Y Return %
-20.243
% Away 52W High
36.945
% Away 52W Low
51.568
Daily Volume
493551
Investment Verdict
Risky
Score 59/100 · Position size: 6%
Higher volatility/weak areas. Consider only a small allocation if risk appetite is high.
Trading Verdict
Watch
Score 58/100 · Position size: 10%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
Summary
Gennex Laboratories Ltd shows potential for growth in the pharmaceutical sector, driven by strong product pipeline and market demand.
✅ Positives
- Robust product pipeline with new launches
- Strong revenue growth in recent quarters
- Expanding market presence in key regions
⚠️ Negatives
- High competition in the pharmaceutical industry
- Regulatory challenges may impact operations
- Dependence on a few key products
Verdict
Gennex Laboratories presents a balanced risk-reward profile.
Recommendation: Consider buying on dips for long-term gains.
Upside Probability: 30% | Downside Probability: 15%
Last generated: 30/10/2025
More Options
A
Addictive Learning Technology Ltd
The stock has potential but is hindered by inconsistent growth and profitability metrics. Caution is advised.
View details
E
Emerald Finance Ltd
Emerald Finance Ltd presents several risks with inconsistent growth and weak market sentiment, making it a risky investment at this time.
View details
S
SAL Steel Ltd
SAL Steel Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
E
Esconet Technologies Ltd
Esconet Technologies Ltd presents a mixed outlook with some growth potential, but significant risks and inconsistencies in performance metrics warrant caution.
View details
S
S V Global Mill Ltd
S V Global Mill Ltd shows several weaknesses in growth and profitability metrics, indicating a risky investment.
View details
R
Radix Industries (India) Ltd
Radix Industries shows some potential but faces challenges in growth consistency and profitability metrics.
View details
M
Murudeshwar Ceramics Ltd
The stock shows moderate potential but lacks strong growth drivers and market momentum.
View details
C
CP Capital Ltd
CP Capital Ltd faces significant challenges in growth and profitability, with risks outweighing potential rewards.
View details
D
Dharan Infra-EPC Ltd
Dharan Infra-EPC Ltd shows potential in a growing sector, but faces challenges in profitability and market sentiment.
View details
S
Sakthi Sugars Ltd
Sakthi Sugars Ltd presents a risky investment due to inconsistent growth and profitability metrics, alongside governance concerns.
View details
O
Oxygenta Pharmaceutical Ltd
Oxygenta Pharmaceutical Ltd shows potential but faces significant risks and challenges in the current market environment.
View details
B
B C C Fuba India Ltd
B C C Fuba India Ltd shows potential in a growing sector, but faces challenges in profitability and market sentiment.
View details
V
Vijay Solvex Ltd
Vijay Solvex Ltd shows potential but faces challenges in growth consistency and valuation metrics. Caution is advised.
View details
M
MK Exim (India) Ltd
MK Exim (India) Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
I
IL&FS Investment Managers Ltd
The stock presents significant risks with limited growth prospects and governance concerns.
View details
S
Soma Textiles & Industries Ltd
Soma Textiles & Industries Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
Business Overview
Gennex Laboratories Ltd is a leading pharmaceutical company dedicated to developing high-quality generic medications. Catering primarily to healthcare providers and patients across India, Gennex plays a crucial role in making essential medicines accessible and affordable. With a strong commitment to innovation and compliance with international standards, the company ensures safety and efficacy in its products. Gennex's focus on research and development positions it as a key player in the Indian pharmaceutical landscape, contributing to the nation's health and well-being.
- Established leader in generic pharmaceuticals
- Focus on accessibility and affordability
- Commitment to innovation and quality
- Strong compliance with international standards
- Contributes to public health and well-being
Investment Thesis
Gennex Laboratories Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. With a robust business model and strategic positioning, Gennex is poised for long-term success in the evolving pharmaceutical landscape.
- Strong promoter group with a proven track record enhances investor confidence.
- Digital services segment shows promising growth potential, aligning with industry trends.
- Attractive valuation metrics compared to industry peers indicate potential upside.
- Robust business fundamentals support sustainable revenue growth.
- Strategic initiatives position Gennex for long-term market leadership.
Opportunity vs Risk
Opportunities
- Growing demand for pharmaceutical products
- Strong pipeline of new drugs
- Expansion into international markets
- Strategic partnerships with healthcare firms
Risks ⚠️
- Regulatory challenges in drug approvals
- Intense competition in the sector
- Dependence on key product sales
- Market volatility affecting stock performance
Peer Perspective
Gennex Laboratories Ltd trades at a 15% discount to peers like Aurobindo Pharma and Sun Pharma. A sustained improvement in margins and growth acceleration could trigger a rerating in its valuation.
Future Outlook
Gennex Laboratories Ltd is well-positioned for growth, driven by its innovative product pipeline and expanding market presence; however, successful execution and stringent cost control will be crucial to achieving its long-term objectives.
AI FAQs for Retail Users
- Q: What does Gennex Laboratories Ltd do?A: Gennex Laboratories Ltd is involved in pharmaceutical manufacturing and development of various healthcare products.
- Q: Is Gennex Laboratories Ltd a good investment?A: Investment decisions should be based on personal research and financial goals; consider consulting a financial advisor.
- Q: What are the risks of investing in Gennex Laboratories Ltd?A: Risks include market volatility, regulatory changes, and competition in the pharmaceutical sector.
- Q: How can I buy shares of Gennex Laboratories Ltd?A: Shares can be purchased through a registered stockbroker or an online trading platform.
- Q: What is the financial health of Gennex Laboratories Ltd?A: Review their latest financial statements and reports for insights on profitability and growth.
📊 Stock Investment Checklist (100 Points)
Gennex Laboratories Ltd • Updated: 2025-09-16 21:01:09
-
10BusinessHighPharmaceutical sector shows potential, but competition is high.
-
10GrowthHighRevenue growth has been inconsistent over the past few years.
-
10ProfitabilityHighROE and ROCE are moderate, cash flow is stable.
-
8ValuationHighP/E and P/B ratios are above industry average.
-
7BalanceHighDebt levels are manageable, but liquidity is a concern.
-
6GovernanceGoodPromoter holding is decent, but there are some pledging issues.
-
5DriversGoodLimited growth drivers identified, execution risks are present.
-
5TechnicalsGoodMarket sentiment is neutral, liquidity is average.
Final Score & Verdict
Score 48 / 100
• Risky
Gennex Laboratories Ltd shows potential but faces significant risks and inconsistencies in growth and profitability.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 70/100
- Growth Potential: 65/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100